Mucormycosis in CAPA, a Possible Fungal Super-Infection

Abstract

The occurrence of pulmonary fungal superinfection due to Aspergillus spp. in patients with COVID-19 is a well-described complication associated with significant morbidity and mortality. This can be related to a directed effect of the virus and to the immunosuppressive role of the therapies administered for the disease. Here, we describe the first case of pulmonary infection due to Mucorales occurring in a patient with a concomitant diagnosis of COVID-19-associated pulmonary aspergillosis.

Pulmonary mucormycosis in the aftermath of critical COVID-19 in an immunocompromised patient: Mind the diagnostic gap

“…False positive results of GM in serum have previously been seen in patients receiving beta-lactam treatment [15] , however our patient had finished the course of piperacillin/tazobactam 3 days before blood sampling for GM was done. Reports of mucormycosis cases with positive GM have been published previously [ 16 , 17 ] , as well as reports of CAM cases with concomitant aspergillosis [ 18 , 19 ].…”

Mucormycosis an added burden to Covid-19 Patients: An in-depth systematic review

“…In patients with active infection caused by pathogens (e.g., SARS CoV-2) an increased incidence of fungal infection (e.g. aspergillosis [11] , cryptococcosis, candidiasis [12] , [13] , Coccidioides [14] , Geotrichum [15] Fusarium [16] , Mucorales [17] Mucorales+Aspergillus [18] Pneumocystosis [19] , Mucormycosis, Histoplasmosis) was detected [20] . Finally it has been observed that excessive use of steroid drugs make patients susceptible to mucormycosis which can occur anytime during hospitalization or after hospitalization [21] .…”